



CEDARS-SINAI TECHNOLOGY VENTURES
THE SPECTRUM OF
INNOVATION

CONTENTS

- 2 Innovation:
Our Mission
- 4 The Spectrum
of Innovation
- 6 Cedars-Sinai
Intellectual
Property
Company
- 14 Cedars-Sinai
Accelerator
- 20 Cedars-Sinai
Health Ventures
- 24 Global Partners
- 26 Our Team
- 29 Contact Us

Globally, life expectancy has more than doubled in the last 200 years.

This remarkable achievement can be attributed to a combination of factors, including advancements in public health measures, improved living conditions, and socio-economic developments.

But without exceptional innovations in medicine—the development of vaccines and antibiotics, advances in medical technology, diagnostic tools, and treatment options—our ability to eradicate, detect and manage many diseases would be greatly diminished.

Several emerging medical technologies hold great promise to further improve healthcare in the future: precision medicine, genome editing, nanomedicine, regenerative medicine and mRNA vaccines—not to mention the rapidly developing fields of virtual reality, augmented reality, generative artificial intelligence and machine learning. These are some of the notable areas where advancements are expected to make a significant impact.

Investments in leading-edge and forward-thinking biomedical science along the entire spectrum of innovation will lead to groundbreaking solutions that can further enhance diagnostics, treatment efficacy, and patient outcomes—ultimately contributing to longer life expectancy and improved quality of life.

This is our focus.

This is our vision.

This is how Cedars-Sinai Technology Ventures transforms ideas into healing.

INNOVATION:

THE IMPACT OF INNOVATION

At Cedars-Sinai, we deliver exceptional healthcare enhanced by research and education. Innovation is integral to that mission in myriad ways.

Our fundamental purpose is to heal. Cedars-Sinai Technology Ventures works to advance this purpose with imagination and enthusiasm for new ideas and approaches. Each of our three core initiatives contributes to the effort.

Cedars-Sinai Intellectual Property Company helps turn ideas developed by our faculty into viable innovations. Its patent portfolio generates millions of dollars each year to support Cedars-Sinai's basic and translational biomedical research efforts.

The Cedars-Sinai Accelerator assists growing healthcare startup companies in tailoring their solutions for maximum impact, with mentorship, funding and access to the resources, personnel and network of a world-class academic medical center.

Cedars-Sinai Health Ventures invests in the expansion of companies with viable products and services likely to be adopted by Cedars-Sinai.

Together, these initiatives advance innovation across the full spectrum, with the goal of improving health outcomes at Cedars-Sinai, in our community and around the world.

OUR MISSION


By combining traditional technology transfer activities with a program focused on early-stage startups and a venture fund that supports later-stage companies, we're able to engage and support inventors and entrepreneurs along the spectrum of innovation—and maximize our ability to drive success.

JAMES D. LAUR, JD

**Chief Intellectual Property Officer, Cedars-Sinai
Managing Director, Cedars-Sinai Health Ventures**

THE SPECTRUM

Cedars-Sinai operates along the full spectrum of innovation, from bringing nascent ideas to life, helping startup companies launch new products or bolstering established companies' expansion into new markets. Individually, our three core initiatives—Cedars-Sinai Intellectual Property Company, Cedars-Sinai Accelerator and Cedars-Sinai Health Ventures—have enhanced our reputation as a leader in the innovation space. These initiatives are part of a coordinated and focused strategic vision which supports the companies in our network as they grow into new markets and expand their impact on global healthcare.



Cedars-Sinai Intellectual Property Company

SUPPORT FOR:

Very early companies exploring a product idea or building the first version of a product, as well as new technologies that need a core team and initial funding. Many internal innovation initiatives at Cedars-Sinai fit into this category.

WHAT WE DO:

- Provide commercial assessment and technical support for product development
- Initial investment or connection to pre-seed/seed venture investors
- Guidance on defining mission, overall strategy, and key milestones

OF INNOVATION

Testing with Alpha Users

Early Feedback

Testing with Beta Users

Iterate Based on Feedback

Pivot if Necessary

Secure Additional Funding

Grow Customer Base

Expand Team

Add New Partners and Channels

Enter New Markets

Ideate New Products

→ **VALIDATION** → **ITERATION** → **SCALE** → **EXPANSION**

Cedars-Sinai Accelerator

SUPPORT FOR:

Companies which have developed an initial product and are ready to enter the B2B market. The founding team is in place and has typically raised some seed funding to support the product launch. The company often has a small number of early customers.

WHAT WE DO:

- Provide stakeholder feedback on product/market fit and business case
- Give access to a broad user base to drive product improvement and iteration
- Give guidance on sales process and cycle
- Refine messaging on value proposition to resonate with target customers

Cedars-Sinai Health Ventures

SUPPORT FOR:

Companies which have already raised a significant amount of funding but are looking to scale their product or to target larger customers. These companies typically have initial market validation. Cedars-Sinai is a key customer.

WHAT WE DO:

- Provide clinical and stakeholder feedback on product, business case and messaging
- Invest primarily in Series A and B rounds
- Make introductions to other health system customers and to an established network of venture firms



CEDARS-SINAI INTELLECTUAL PROPERTY CO.

Dedicated to turning ideas and inventions into reality, Cedars-Sinai Intellectual Property Company manages a diverse portfolio of more than 100 licenses that has generated over \$150 million in revenue in the last five years, including therapeutics, devices, diagnostics and software. We work to identify, protect and support the commercialization of discoveries and technologies developed at Cedars-Sinai or by our partner institutions.

This work extends beyond a traditional technology transfer strategy to encompass a wide range of financial and venture approaches that transform ideas into new products and services for the healthcare market.

Our focus is on the very early stages of development—exploring a product idea or building the first version of a product. We provide commercial assessment and technical support for product development and help build core development teams. We make initial investments or connect inventors to pre-seed/seed venture investors. We provide guidance on defining mission, overall strategy and key milestones.

FOUR HISTORIC BREAKTHROUGHS

Patients around the world benefit from decades of inventions developed at Cedars-Sinai, part of its ongoing commitment to conducting innovative research and providing superior healthcare. Hundreds of active technologies currently in development have the potential to push the boundaries of medicine even further.

The four groundbreaking inventions highlighted here originated in Cedars-Sinai's laboratories and went on to radically transform the practice of medicine. They underscore the critical work that clinicians, researchers and the Cedars-Sinai Intellectual Property Company team undertake to create and develop novel diagnostics, therapeutics, devices and software.

1970 SWAN-GANZ CATHETER

More than 50 years ago, two Cedars-Sinai physicians, **Jeremy Swan, MD, PhD**, and **William Ganz, MD**, changed the course of cardiology with the invention of the Swan-Ganz catheter. The landmark device, still used more than a million times a year in the U.S. alone, measures blood flow and pressure to the heart and lungs.

But at the time of the catheter's development, Cedars-Sinai lacked an office responsible for new inventions. Swan and Ganz sold their revolutionary device for a mere \$10,000. To prevent another lost opportunity, Cedars-Sinai established the Patent and Invention Policy, which is implemented by the Cedars-Sinai Intellectual Property Company.

IDEAS BECOME

1984 FACTOR VIII

Alan Rubinstein, MD, searched for a way to minimize the effects of undesirable microorganisms in the blood-clotting agent factor VIII, a concentrate used to improve blood clotting in patients with hemophilia. The concentrates are typically prepared from pools of plasma contributed by thousands of donors, and can potentially contain hepatitis, HIV and other pathogens.

Previously, heat treating plasma was not a viable option because it reduced or eliminated clotting-factor activity. Rubinstein's breakthrough process for heating the plasma in a lyophilized form—essentially freeze-drying it—provided a method to inactivate unwanted microorganisms without reducing clotting-factor activity.

1991 BARATH CUTTING BALLOON

Cardiologist **Peter Barath, MD**, noticed that an unusually high number of patients who underwent angioplasties returned months later with re-narrowing of the arteries, a condition called restenosis. He set out to develop a device to reduce the risk of damaging artery walls during percutaneous coronary interventions. The result is the Barath Cutting Balloon, which is now used in percutaneous angioplasty to reduce re-injury and avoid uncontrolled disruption of the atherosclerotic plaque.

The technology was developed with a small device company that licensed the invention from Cedars-Sinai. The company was later acquired by Boston Scientific, which made Barath's balloon available throughout the world. Sales of the device now exceed \$100 million annually.

2003 RIFAXIMIN FOR IBS

When **Mark Pimentel, MD**, began to explore whether a bacterial infection could be a factor behind irritable bowel syndrome (IBS), he opened the door to a new understanding of the disease. Previously, IBS was viewed as a psychological disorder brought on by stress. Pimentel began studying rifaximin, an antibiotic prescribed to treat traveler's diarrhea, because—unlike some other antibiotics—it did not seem to generate drug-resistant bacteria. He went on to discover that rifaximin provided IBS patients with long-lasting relief even after they stopped taking the medication.

Rifaximin is now approved for this use by the Food and Drug Administration (FDA), with annual sales in excess of \$2 billion.

TECHNOLOGIES

FIVE EMERGING TECHNOLOGIES

The synergy of research and clinical care at Cedars-Sinai continues to fuel important discoveries—and the network of partnerships developed by Technology Ventures further expands our ability to convert those discoveries into tools for improving health outcomes. These current examples—ranging from promising projects to proven successes—demonstrate the breadth of expertise that allows us to continue the innovation that began over half a century ago with the Swan-Ganz catheter.

PROMETHEUS BIOSCIENCES IBD TREATMENT

No cure and few treatment options exist for patients suffering from Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD).

Stephan Targan, MD, Dermot McGovern, MD, PhD, and Janine Bilsborough, PhD, have cracked the code to a better understanding of the disease. The trio lead a group of scientists studying cytokine TL1A and the role it plays in Crohn's disease. In mice, the team reproduced the disease and effectively neutralized the effects of the TL1A antibody.

The results were so promising that Technology Ventures helped form the start-up company which subsequently became Prometheus Biosciences, to develop novel drug treatments. In addition to managing and protecting the complex intellectual property involved in this endeavor, Technology Ventures was instrumental in forming key strategic partnerships.

In December 2022, Prometheus announced positive results from two Phase 2 studies evaluating safety and efficacy in patients. In June 2023, Prometheus was acquired by Merck for approximately \$10.8 billion in a cash transaction.

PANCSURE PANCREATIC CANCER SCREENING

Over the past 30 years, no significant improvement has been made in the testing methods clinicians use to diagnose pancreatic ductal adenocarcinoma (PDAC). That lack of innovation has had devastating consequences for patients, with a median overall survival of just five to six months. However, a new test is providing hope.

Stephen J. Pandol, MD, and Simon Lo, MD, are heading up a project to develop a noninvasive test for the early detection of PDAC that could significantly improve outcomes for pancreatic cancer patients. PDAC test development is focusing on validating usefulness and accuracy of a new urine analysis tool based on the discovery of three biomarkers that can detect pancreatic cancer in patients with greater than 90% accuracy.

Cedars-Sinai Technology Ventures, through its business unit 3rd Street Diagnostics, and in partnership with the Samuel Oschin Comprehensive Cancer Institute, DxD Hub, the diagnostics development platform of Singapore's Agency for Science and Technology Research (A*STAR) and Queen Mary University of London, is leading the effort to bring the PDAC urine test to clinics.

3rd STREET DIAGNOSTICS INFLAMMATORY AND AUTOIMMUNE DISORDER TREATMENT

Current autoimmune disorder treatments are largely non-specific with steroids and drugs like cyclosporine and tacrolimus. While newer agents show promise, there remains a need for drugs that can treat these conditions directly by modulating the immune system.

Under their nephrology and transplant research programs, **Stanley Jordan, MD**, and **S. Ananth Karumanchi, MD**, are leading a project to develop a new protein drug that has the potential to provide a better treatment option for a wide variety of immune-mediated autoimmune and inflammatory diseases, as well as transplantation.

The potential for the drug to provide new treatment strategies in autoimmune, chronic inflammatory diseases, and transplant rejection led Technology Ventures to co-create the startup company Mitera Biosciences to bring this scientific discovery to the clinic.

GEMELLI BIOTECH MICROBIOME-BASED TREATMENTS

Led by **Mark Pimentel, MD**, **Ruchi Mathur, MD**, and **Ali Rezaie, MD**, the Medically Associated Science and Technology (MAST) program at Cedars-Sinai develops novel drugs and devices to diagnose and treat illnesses related to imbalances or alterations in the microbiome—particularly metabolic, gastrointestinal function and motility disorders.

Technology Ventures' hybrid partnership with MAST provides focused strategic direction and project-specific support to expedite the translation of new technology into commercial products.

One result of that partnership is Gemelli Biotech, co-founded by Pimentel to market *ibs-smart*[®], a second-generation blood test for Irritable Bowel Syndrome (IBS). That success was followed by *trio-smart*[®], a breath test that provides a complete profile of the primary fermented gases in the microbiome by measuring the levels of hydrogen, methane, and hydrogen sulfide in a patient's breath to determine if any are abnormally elevated.

In 2019, Gemelli Biotech Corp. announced the completion of a \$19 million Series A financing round.

GRAVIDAS PREECLAMPSIA TEST

Preeclampsia is a severe pregnancy complication and a leading cause of maternal and perinatal morbidity and mortality, affecting 5 to 8% of all pregnancies. The condition is difficult to recognize and current testing is not highly accurate or predictive, often leading to misdiagnosis that can result in a rapid progression to severe disease and premature delivery.

To help advance the understanding of preeclampsia and bring a point-of-care test to patients, Cedars-Sinai's **S. Ananth Karumanchi, MD** and **Anders Berg, PhD, MD**, together with former Cedars-Sinai vice dean of research **Ravi Thadhani, MD, MPH**, have designed a blood test based on the discovery that preeclampsia patients show elevated levels of a certain protein, sFlt-1.

Led by **Nirdesh Gupta, PhD**, Gravidas was founded in 2021 to develop this important POC test in partnership with Technology Ventures. Gravidas is now working towards submission of a 510(k) with the FDA to bring it to market and improve maternal care and perinatal outcomes first in the U.S., then internationally.

INVENTIONS GENERATE INSIGHT AND REVENUE

239 Treatments
or Preventions

188 Diagnostics
or Tests

85 Medical
Devices

70 Research
Tools

67 Digital or
Software
Solutions

1/3 of all inventions
are licensed
or optioned

**MORE THAN \$150
million**

licensing revenue in the last 5 years



Technology Ventures' endorsement of the vision and conviction of Prometheus' founders—and its steadfast support of the company through the ups and downs of development—paid off in the end.




DERMOT McGOVERN, MD, PhD
Co-Founder, Prometheus Biosciences

CEDARS-SINAI ACCELERATOR

Healthcare is a complex industry, and building a successful company takes more than a great idea. The Cedars-Sinai Accelerator helps entrepreneurs develop and scale innovative business models through mentorship, guidance and investment. Our goal is to boost the development of the next generation of biomedical enterprises that will transform care at Cedars-Sinai and beyond.

Since 2016, the Accelerator has supported early-stage ventures developing solutions to improve healthcare and healthcare delivery. Those accepted into the program spend three months working closely with mentors from Cedars-Sinai and beyond to accelerate the creation, growth and traction of their products and companies. Close collaboration with clinicians, executives, researchers, and other experts fosters a deep understanding of the needs of patients and providers. Acceptance into the program comes with a \$100,000 investment award, in addition to invaluable insight and guidance from our network of mentors and subject-matter experts.

At the end of the program, all participating founders present their product to an invited group of investors, potential customers and the media during a Demo Day hosted by Cedars-Sinai. Over 90 companies have participated in the program to-date, creating a strong community of biomedical entrepreneurs who share Cedars-Sinai's mission of improving healthcare through innovation.



FIVE INNOVATORS TO WATCH

Successfully navigating the complex practical, financial and regulatory challenges of growing a young company in the healthcare space is difficult. These five firms are all thriving—and enriching the healthcare landscape around the world—thanks in part to their participation in the Cedars-Sinai Accelerator program.

ARTERA ACCELERATOR CLASS 1, 2016 PATIENT COMMUNICATION PLATFORM

Artera is a communication platform connecting patients to providers via text, phone, email and live chat. Artera improves efficiency through reductions in call volume and no-show rates, unifies outreach across software applications and delivers an improved customer experience.

Artera Harmony, the company's next-generation SaaS patient engagement platform, streamlines patient communications, minimizes message overload and consolidates multiple channels for personalized care delivery.

In February 2024, Artera secured \$22 million in additional capital through several large investment funds and influx from individual investors. The funding will support the international expansion and commercial growth of the company.

TASSO ACCELERATOR CLASS 3, 2018 REMOTE BLOOD-COLLECTION DEVICE

The Tasso+ device is a user-friendly way to self-collect blood for clinical diagnostics, clinical researchers, and wellness solutions. The device, enabled by microfluidic technology, can replace phlebotomy in small clinics and enable in-home blood collection.

In combination with the Tasso+ device, the company offers a complete solution to reliably power decentralized clinical trials. Tasso's integrated logistics platform supports shipping, participant engagement and more. The fully integrated Tasso Connect portal tracks samples and data, and connects seamlessly with clients' systems through API integration.

Tasso+ is the first device of its kind to have achieved full clearance in both the U.S. and the European Union.

PARTNERSHIPS G

DILIGENT ROBOTICS

ACCELERATOR CLASS 6, 2021

AI SUPPORT ROBOTS

Diligent Robotics is a human-centered robotics company engaged in developing a suite of artificial intelligence tools that enables robots to collaborate with and adapt to humans in everyday environments.

Their hospital-service robot, Moxi, can assist clinical staff with logistical tasks, allowing them to spend more of their time on direct patient care, improving patient satisfaction, quality of service and safety.

In September 2023, Diligent Robotics announced a \$25 million capital infusion. The funding will boost production and R&D, as the company looks to triple its reach in the U.S.

AEVICE HEALTH

ACCELERATOR CLASS 8, 2023

RESPIRATORY MONITORING DEVICE

Aevice Health is a Singapore-based company at the forefront of chronic respiratory disease management with non-invasive wearable devices enabling early detection of abnormalities. AeviceMD is part of the broader AeviceMD Monitoring System, which continuously monitors biomarkers of interest acquired by its smart wearable stethoscope.

In July 2023, AeviceMD received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device, allowing the company to provide their remote monitoring platform to providers across the country.

Aevice is about to close their Seed Plus round with an \$8 million goal. Coronet Ventures (Singapore) is the lead investor with \$2 million. Other investors include SEEDS Capital, East Ventures, A&D Company, NTUitive and Silicon Solutions Ventures.

SYNTHO

ACCELERATOR CLASS 8, 2023

AI-GENERATED SYNTHETIC DATA

Cedars-Sinai is collaborating with Syntho, an Amsterdam-based company that is exploring the potential of artificial intelligence in generating synthetic data sets that replicate real patient information—enabling an open-data economy while safeguarding patient privacy.

Traditional patient data is sensitive and restricted by privacy laws, making it difficult to utilize for predictive health analysis—particularly by external parties. However, AI-generated synthetic data offers a solution and provides valuable information devoid of identifiable patient details. Syntho's advanced technology achieves this balance between privacy and utility, surpassing conventional anonymization techniques.

In May 2021, Syntho secured a first round of investment of €1 million from TIIN Capital's Dutch Security TechFund.

ROW SOLUTIONS

HELPING COMPANIES GROW

80%

of Accelerator alumni companies have raised additional investment at 6 months post program

\$849 million

total raised by alumni companies, \$676 million post program

85%

of alumni companies are still active or have been acquired

\$10 million

follow-on investment by Cedars-Sinai in select alumni companies



“ We help companies accomplish in three months what would otherwise have taken them two years. ”

NIRDESH GUPTA. PhD
Managing Director,
Cedars-Sinai Technology Ventures



CEDARS-SINAI HEALTH VENTURES

Throughout the global healthcare system there is no shortage of problems that need solving—diseases to be cured and chronic conditions to be managed, but also staffing shortages, rising costs and other seemingly endless challenges. Healthcare and technology innovators around the world are searching for solutions to these myriad problems. The team at Cedars-Sinai Health Ventures are creating new ways to drive the solutions.

How can a venture capital fund make a difference in this complex environment?

By asking hospital leaders what they need, and investing time, expertise and capital in the young companies that might bring solutions to the problems at the top of the list.

Startups are making important strides on many fronts, from leading-edge computational biomedicine to the logistics of delivering care in a diverse and sprawling region like Southern California. Cedars-Sinai Health Ventures is identifying and nurturing the most promising companies striving to provide innovations that enable improved and cost-effective patient care.

KEY INVESTMENT DATA

**\$10
million**
deployed

4 core
fund
investments

INVESTMENTS AS OF 01/2024

Pilot/commercial
engagement with

100%
of the portfolio

INVESTMENTS IN THE NEAR FUTURE

The investments that Cedars-Sinai Health Ventures makes are carefully chosen.

Each of these companies is creating a product that we believe could soon be of great value to the healthcare industry in general—and to Cedars-Sinai patients and physicians specifically.

INVESTMENTS F

HEALTH NOTE
FOUNDED 2018
PATIENT INTAKE/EHR PROGRAM

Health Note is a clinically intelligent patient-intake system that simplifies the process of documenting every physician-patient interaction. The platform creates an improved experience for care teams and patients by updating EMR data and automating clinical notes. It reduces the EMR workload for clinicians and front office staff; helps healthcare providers collect, organize and document patient information; and empowers patients before, during and after visits.

The company raised \$17 million in its Series A financing round. Cedars-Sinai Health Ventures invested in Health Note on the belief that this technology and application can further strengthen caregiver-patient relationships and help provide personalized medical expertise that efficiently addresses a patient's individual concerns and circumstances.

RxREDEFINED
FOUNDED 2018
DMEPOS PLATFORM

RxRedefined is a patented platform that provides a compliance-focused foundation for physician-owned suppliers of durable medical equipment, from licensing to order processing and billing. The platform allows physicians to personally manage the distribution of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) directly to patients. There are no handoffs and patients can work one-on-one with their provider to get the exact product needed. RxRedefined creates a value-added service to medical practices, reduces patient-care gaps and has demonstrated a reduction in utilization compared to traditional delivery pathways.

The company has experienced rapid growth in urology and is working with Cedars-Sinai as they expand into diabetes treatment.

RHYTHMSCIENCE
FOUNDED 2019
CARDIAC DATA MANAGEMENT

RhythmScience was founded to empower clinicians and doctors with the tools they need to harness cardiac data and improve patient care. Their cloud-based software simplifies follow-up of remote and in-person cardiac devices and data to manage patients requiring hypertension, heart failure and heart rhythm management.

In 2023, the company closed its Series A funding with \$6 million. The investment, led by Cedars-Sinai Health Ventures with participation from new investor OCA Ventures and existing investor TenOneTenVentures, will help drive the cutting-edge technology of the Rhythm360® monitoring platform, which supports Cedars-Sinai's mission to set new standards for quality and innovation in healthcare delivery systems and patient care.

UND NEW IDEAS

GLOBAL PARTNERS

While the U.S. accounts for nearly 50% of global healthcare expenditures, talent and innovation in the healthcare industry can be found worldwide. Cedars-Sinai Technology Ventures has been building international relationships for more than two decades, helping to identify and nurture promising biotechnology partners and bring innovative medical solutions to patients around the world. Some of these relationships have grown into significant partnerships and investments.



THE NETHERLANDS **NBSO/SCALE NL**

The Netherlands Business Support Office (NBSO) in Los Angeles supports Dutch entrepreneurs exploring business opportunities in the greater Los Angeles area. It is one of 22 such offices in 11 countries, supported by the Dutch Ministry of Foreign Affairs and coordinated by the Netherlands Enterprise Agency. Scale NL is a public-private organization that helps Dutch technology entrepreneurs enter and thrive in the U.S.

Cedars-Sinai Technology Ventures has held a number of office hours and pitch sessions arranged by NBSO and ScaleNL, enabling us to foster connections with numerous Dutch health-tech startups. During Dutch Innovation Week, the Technology Ventures team hosted 10 health-tech startups to provide a brief introduction to the U.S. healthcare landscape and match them with mentors and clinicians from Cedars-Sinai.

NBSO introduced to Cedars-Sinai the Dutch startup company Syntho, who went on to become an Accelerator alumni (see page 17).



THE UNITED KINGDOM KHP VENTURES

KHP Ventures started as a collaboration among King's College London, King's College Hospital NHS Foundation Trust, and Guy's and St Thomas' Hospital NHS Foundation Trust but has expanded to include other institutions that share a focus on driving innovation in healthcare. As the first NHS-anchored venture fund, they invest in promising early-stage digital health and MedTech and support their validation, adoption and scale.

The Technology Ventures, Accelerator and Global Alliances team hosted six of KHP Ventures' portfolio startup companies in February 2023 for UK Innovation Exchange Week.

KHP Ventures in turn hosted a Technology Ventures team in June 2023 for an outgoing innovation exchange week when six of our Accelerator alumni companies visited them to learn more about the British National Health System and how to do business in the UK.

Through our subsidiary, Coronet Ventures (Jersey) Pte. LLC, Cedars-Sinai Intellectual Property Company has become a limited partner in their fund.



SINGAPORE CORONET VENTURES

Coronet Ventures (Singapore) PTE. LTD. is the Singapore-based venture entity of Cedars-Sinai Intellectual Property Company (CSIP). They identify and invest in early-stage healthcare and biomedical science startups in Singapore who are looking to focus on the U.S. healthcare market. The first international investment vehicle for CSIP, Coronet Ventures (Singapore) is focused on solutions that are aimed at the U.S. market and that are synergistic with Cedars-Sinai's areas of excellence.

In addition to investment capital, Coronet Ventures (Singapore) facilitates access to clinical experts at Cedars-Sinai to help startup companies validate their solutions in a clinical setting.

Coronet Ventures (Singapore) portfolio companies have access to the Cedars-Sinai Accelerator's network of alumni mentors, and CSIP support for intellectual property protection, FDA submissions, and licensing and commercializing technologies.

SEEDS CAPITAL

SEEDS Capital is the investment arm of Enterprise Singapore, a governmental agency that champions enterprise development and supports the growth of Singapore as a hub for global trading and startups.

SEEDS Capital has appointed Coronet Ventures (Singapore) as a co-investment partner under the Startup SG Equity scheme to jointly invest in Singapore-based startups in the healthcare and biomedical space.

Beyond access to funding, the partnership gives Singapore-based startups the opportunity to tap Cedars-Sinai's wide network of clinical resources and expertise. This includes exposure to research infrastructure for clinical pilot tests, as well as mentorship opportunities from world-leading physicians, researchers, and global healthcare entrepreneurs.

Singapore-based medical device startup Aevice, a Cedars-Sinai Accelerator alumni company and portfolio company, was introduced to us via SEEDS/Enterprise Singapore (see page 17).

OUR TEAM

Innovation defines the lengthy and complicated process of transformation that turns an idea into a technological product or process meant for widespread adoption and practical use. By this definition, a single person or even a single group cannot alone create and innovate. Technology Ventures, through the Intellectual Property Company, the Accelerator, and Health Ventures, provides vital support networks that nurture innovation.



DAVID M. WRIGLEY
*Executive Vice President
and Chief Financial Officer,
Cedars-Sinai Health System*



JAMES D. LAUR, JD
*Chief Intellectual Property Officer,
Cedars-Sinai
Managing Director,
Cedars-Sinai Health Ventures*



NIRDESH K. GUPTA, PhD
*Managing Director,
Cedars-Sinai Technology Ventures
Chief Executive Officer,
Coronet Ventures (Singapore)*



MAUREEN BURGESS, JD
Partner,
Cedars-Sinai Health Ventures



ERIC R. SEE
Director, Operations,
Cedars-Sinai Technology Ventures



PETER S. PARK, JD
Director, Business Operations,
Cedars-Sinai Technology Ventures

**CEDARS-SINAI
TECHNOLOGY VENTURES**

JULIEN BROHAN, MS, CLP
*Manager, Business Development
and Licensing*

WENYUE DU, PhD
*Manager, Business Development
and Licensing*

KINSHUK KOCHER, MBA
Manager, Investments and Special Projects

EMILY MACK
Program Manager, Global Alliances

JIAN TAJBAKSHI, PhD
Senior Research Project Advisor

**CEDARS-SINAI
ACCELERATOR**

OMAR PEREZ
*Manager, Business Development
and Strategic Alliances*

SAMANTHA SHOBASH
*Manager, Operations and
Program Development*

**CEDARS-SINAI
HEALTH VENTURES**

NEMARIAM MESFIN
Fractional CFO


ROHIT RAJKUMAR
Investment Director

**CORONET VENTURES
(SINGAPORE)**


COLIN TAN
Investment Director



To learn more about our team,
scan the QR code or visit
[cedars-sinai.edu/research/
technology-innovations/team.html](https://cedars-sinai.edu/research/technology-innovations/team.html)



‘Bench to bedside’ is a somewhat overused concept but Cedars-Sinai’s Technology Ventures actually has the in-house expertise and structure to make that transition happen. This not only speeds new tools to clinicians—it also helps us recruit the finest minds to conduct their research here.



JEFFREY A. GOLDEN, MD

Director, Burns and Allen Research Institute

Executive Vice Dean, Research and Research Education

Department of Academic Affairs, Cedars-Sinai

CONTACT US:

CEDARS-SINAI INTELLECTUAL
PROPERTY COMPANY

PHONE +1 310 423-0326

EMAIL cstechtransfer@csbs.org

cedars-sinai.edu/techtransfer

 [cedars-sinai technology ventures](#)

CEDARS-SINAI ACCELERATOR

EMAIL csaccelerator@csbs.org

csaccelerator.com

 [cedars-sinai accelerator](#)

CEDARS-SINAI HEALTH VENTURES

PHONE +1 310 423-0326

EMAIL maureen.burgess@csbs.org

cedarssinaihv.com



TECHNOLOGY VENTURES

8721 Beverly Boulevard.
Los Angeles, California 90048

PHONE +1 310 423 1898

cstechtransfer@cshs.org